Innovative Health announced on Monday that it scored FDA clearance to reprocess St. Jude Medical’s ViewFlex Xtra Diagnostic Ultrasound Catheter. “Reprocessing is changing,” Rick Ferreira, CEO of Innovative Health, told HCB News. “It used to be about mimicking manufacturer technique on low-complexity devices late in their life cycle. SUD reprocessing is increasingly about understanding clinical …
Encore Dermatology Inc. announces today the availability of a new topical product, IMPOYZ Cream, indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. IMPOYZ Cream is the only FDA-approved high-potency topical corticosteroid with 0.025% clobetasol propionate.
Genoptix, Inc., a leading oncology diagnostic laboratory today announced that Rosetta Genomics’ stockholders have approved the acquisition of Rosetta Genomics by Genoptix. Genoptix will immediately begin marketing, selling and distributing the complete Rosetta Genomics portfolio and will ensure the uninterrupted availability of these important products for physicians and patients. Genoptix previously purchased Rosetta Genomics’ precision …
Easing adoption, accelerating commoditization and lowering costs. That’s how it works everywhere else. Why not in healthcare? In my interview of experts from Innovative Health, the largest U.S. medical device reprocessor specializing in cardiology, they all reinforced the same point: hospital decision-makers still must turn the tables on the manufacturer.
Colorescience® is proud to announce the addition of two new members to its Board of Directors, David Olsen and Ty Stiklorius.
Onkos Surgical, Inc. announced today that it signed a 4-year agreement with 3D Systems (NYSE: DDD) to advance the delivery of personalized surgical solutions and help improve patient outcomes.
1315 Capital, LLC, an expansion and growth equity firm that invests in commercial-stage specialty pharmaceutical, medical technology and healthcare services companies, today announced the single close of 1315 Capital II, a healthcare growth equity fund, at its hard cap over $300 million, exceeding its $250 million target. Similar to the first fund, 1315 Capital II …
Colorescience®, the leading dermatologist-recommended skin health-focused skincare and cosmetics company, is proud to introduce the innovative Colorescience Total Eye™ 3-in-1 Renewal Therapy SPF 35. This comprehensive eye product is a strong addition to the brand’s treatment portfolio that includes All Calm™ Clinical Redness Corrector SPF 50, which addresses symptoms of adult acne and rosacea, and …
Genoptix, Inc., a leading oncology diagnostic laboratory, and Rosetta Genomics Ltd. (ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, jointly announce that they have entered into a definitive merger agreement under which Genoptix will acquire all of the outstanding shares of Rosetta Genomics for a …
“Encore is excited about adding another great product to our portfolio and looking forward to the opportunity to commercialize a new product for the treatment of mild to moderate psoriasis as well as broadening our portfolio outside of atopic dermatitis and acne,” said Robert Moccia, CEO, Encore Dermatology, Inc.